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LETTERS
Detection of 
Newly Described 
Astrovirus MLB1 
in Stool Samples 
from Children 
To the Editor: We read with in-
terest the article by Finkbeiner et al. 
describing an epidemiologic survey 
of newly described astrovirus MLB1 
(AstV-MLB1) conducted in the Unit-
ed States in 2008 (1). This study was 
an extension of recently published 
reports of characterization of AstV-
MLB1 from a fecal sample obtained in 
Australia in 1999 (2,3). These studies 
provide evidence of a divergent group 
of astroviruses and their etiologic as-
sociation with human disease.
However, the occurrence of a 
MLB1-like AstV in humans has al-
ready been documented. Walter iden-
tiﬁ  ed a novel AstV in an 8-month-old 
child with diarrhea in Mexico in 1991 
(4). In that study, Walter screened fecal 
samples for AstVs by using a variety 
of techniques. Sequencing of selected 
PCR products identiﬁ  ed a unique vi-
rus that had typical AstV morphologic 
appearance, but was nonreactive with 
human AstV-speciﬁ   c monoclonal or 
polyclonal antibodies. Phylogenetic 
analysis of fragments of open reading 
frame 1a (ORF1a) and ORF2 genome 
regions of this virus strain (M3363) 
showed that it was only distantly relat-
ed to other mammalian AstVs, includ-
ing human AstVs (4). This sequence 
divergence from canonical human 
AstVs suggested that M3363 might 
have been transmitted from an animal 
reservoir (4,5).
When we reanalyzed ORF1a of 
M3363, we found that this strain was 
actually an MLB1-like AstV with >98% 
amino acid similarity to prototype and 
strains from the United States (Figure) 
that dated back to 1991. The fact that 
such closely related viruses were found 
in a scattered temporal and spatial 
pattern in children may indicate that 
MLB1-like AstVs represent a true hu-
man enteric virus, which was probably 
overlooked in the absence of adequate 
diagnostic reagents and protocols.
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In Response: We thank Bányai 
et al. (1) for drawing attention to the 
unpublished data of Walter (2), which 
was not part of the peer-reviewed 
literature at the time we described 
the complete genome of astrovirus 
MLB1 (3) or when we described our 
epidemiologic survey of stools col-
lected in St. Louis, Missouri, USA 
(4). The results of Walter extend the 
known geographic range of astrovi-
rus MLB1 to include Mexico, thus 
supporting our recent proposal that 
astrovirus MLB1 is likely to be glob-
ally widespread (4). We look forward 
to including the partial sequence gen-
erated by Walter in future analyses of 
astrovirus MLB1 genetic diversity. 
We strongly encourage Bányai et al. 
to submit their sequence data to any 
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Figure. Neighbor-joining tree based on partial sequences of open reading frame 1a protein 
of human and animal astroviruses. Amino acid sequences of the Mexican M3363 strain 
(arrow) were obtained from Walter (4); other sequences were obtained from GenBank. 
Bootstrap values >90 are indicated. Scale bar is proportional to genetic distance and 
indicates nucleotide substitutions per site.
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of the publicly accessible and search-
able international sequence databases 
such as GenBank, the European Mo-
lecular Biology Nucleotide Sequence 
Database, or the DNA Database of Ja-
pan so that it can be readily accessed 
by the scientiﬁ  c community.
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Optimal Therapy for 
Multidrug-Resistant 
Acinetobacter 
baumannii
To the Editor: I read with inter-
est the article by Doi et al. about a lung 
transplant patient presumed to have 
Acinetobacter baumannii ventilator-
associated pneumonia (1), but some 
points deserve comment. A. baumannii 
is a relatively avirulent organism that 
frequently colonizes body ﬂ  uids. For 
multidrug-resistant strains, antimicrobi-
al drug selection is limited. Resolution 
of this patient’s pulmonary inﬁ  ltrates 
suggests that they were not caused by 
A. baumannii that persisted in respira-
tory secretions. Because A. baumannii 
persisted in this patient’s respiratory 
secretions, colistin and cefepime were 
given. Colistin is an antimicrobial drug 
with low resistance potential; but when 
given by inhalation, it may lead to drug 
resistance (2,3). 
Doi et al. stated that the patient’s 
A. baumannii strain lacked susceptibil-
ity to all available antimicrobial drugs 
but that cefepime and tigecycline were 
intermediately susceptible (MICs 16 
μg/mL and 2.0 μg/mL, respectively) 
(1). Intermediate susceptibility may 
also be interpreted as relatively sus-
ceptible when achievable serum or 
tissue concentrations exceed the MIC. 
The article did not mention the dosages 
of colistin, tigecycline, and cefepime. 
A 2-g dose of cefepime given intrave-
nously results in peak serum levels of 
≈163 μg/mL with a relatively low vol-
ume of distribution (0.29 L/kg), which 
would not be expected to eradicate A. 
baumannii in respiratory secretions. 
High-dose intravenous tigecycline 
(initial dose of 200 mg followed by 
100 mg daily) has been used to treat A. 
baumannii, achieving peak concentra-
tions of ≈3 μg/mL, which exceed the 
isolate’s MIC of 2 μg/mL, and a high 
volume of distribution (8 L/kg), which 
would be expected to eradicate A. bau-
manii in respiratory secretions.
Optimal treatment for A. bauman-
nii depends on susceptibility, phar-
macokinetic principles, and site of 
infection. For optimal effectiveness, 
cefepime and tigecycline should have 
been given at high doses. To prevent 
potential resistance, antimicrobial 
drugs should not be given by inhala-
tion (3). The alleged advantage of 
inhalation therapy is high local drug 
concentrations, but concentrations in 
some alveoli may be subtherapeutic 
(3). If possible, tigecycline should not 
be used to treat A. baumannii infec-
tions; however, if it is used, high doses 
should be given to optimize its phar-
macokinetic attributes (4,5).
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